iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia

Patients with mutated IGHV (IGHV-M) have promising long-term outcomes after chemotherapy with fludarabine, cyclophosphamide, and rituximab. Based on this knowledge, investigators conducted a phase 2 trial with ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for previously untreated patients with IGHV-M chronic lymphocytic leukemia. The objective of the study was to limit fludarabine and cyclophosphamide to 3 courses, potentially reducing toxicity, while maintaining efficacy through the addition of ibrutinib and obinutuzumab. To be eligible, patients had to be ≥18 years of age with IGHV-M and no del17p. Patients received 3 courses of iFCG. The primary end point was complete response/complete response with incomplete blood count recovery (CR/Cri) with bone marrow (BM) minimal residual disease (MRD)-negativity (4-color flow cytometry) after 3 courses of iFCG.

A total of 23 patients started treatment. The median age of patients was 59 years (range, 25-71 years), and prognostic markers included del13q (n = 17), del13q-negative (n = 3), and trisomy 12 (n = 3). Of the 23 patients who started treatment, 18 completed 3 courses of iFCG and had response at initial assessment. MRD-negativity in BM at 3 months was achieved in 14 of the 18 patients (78%), whereas CR/CRi (all MRD-negative) was achieved in 7 of the 18 patients. No patient has progressed, and all except 1 continue to receive treatment. Patients who received ibrutinib with obinutuzumab for cycles 3 to 6, then ibrutinib for cycles 7 to 12, achieved the primary end point, whereas patients who received ibrutinib with obinutuzumab (cycles 4-12) did not achieve the primary end point. The target BM MRD-negativity after 3 courses of iFCG was 45%. All patients who are MRD-negative at 1 year will stop therapy, including ibrutinib; patients who are MRD-positive at 1 year may continue ibrutinib.

Of the 23 patients, 11 patients had grade 3/4 neutropenia, 5 patients had grade 3/4 thrombocytopenia, 4 patients had neutropenic fever, and 1 patient who achieved MRD-negative CR developed pulmonary Mycobacterium avium complex infection and declined further therapy. Moreover, 1 patient had atrial fibrillation, and grade 3 ALT elevation developed in 3 patients. Consequently, the dose of fludarabine and cyclophosphamide was reduced in 10 patients, and the dose of ibrutinib was reduced in 2 patients.

The results of this study indicate that iFCG achieves a high rate of MRD-negative remission after 3 courses. Patient enrollment is ongoing.

Jain N, et al. ASCO Abstract 7522.

Related Items
Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Last modified: June 9, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME